# Anti-VEGF Therapy for Acute Thyroid Eye Disease

> **NCT04311606** · PHASE2 · COMPLETED · sponsor: **Massachusetts Eye and Ear Infirmary** · enrollment: 11 (actual)

## Conditions studied

- Thyroid Eye Disease

## Interventions

- **DRUG:** Sub-tenon injection of saline followed by a sub-tenon injection of aflibercept
- **DRUG:** Sub-tenon injection of hyaluronidase (HA) followed by a sub-tenon injection of aflibercept
- **DRUG:** Sub-tenon injection of hyaluronidase (HA) alone

## Key facts

- **NCT ID:** NCT04311606
- **Lead sponsor:** Massachusetts Eye and Ear Infirmary
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-02
- **Primary completion:** 2024-12-17
- **Final completion:** 2024-12-17
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2025-12-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04311606

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04311606, "Anti-VEGF Therapy for Acute Thyroid Eye Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04311606. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*